Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We have made it a strategic priority at Thorne to invest in technology and manufacturing that should enable us to realize improved gross margins over time |
| On the top line, Q2 net sales of $72.7 million, represents our highest quarterly sales and record, resulting in growth of 33.1% year-over-year |
| And then from a capacity perspective, our labor costs, while we will be looking to ramp it up slowly, however, full utilization by year 4 will lead to much better overhead absorption |
| So what has happened is this year because of some capacity constraints, we have had to do co-manufacturing and going forward, we expect the benefit of that, that will help us significantly and it will be an immediate benefit in the next 2 years |
| Following completion of the build, we think this new facility will enable us to improve gross margins by another 500 basis points to 600 basis points over the next several years, which would have a significantly positive impact to our overall profitability, resulting in a longer-term gross margin target of approximately 60% for the overall business |
| After posting a very strong first quarter, I am pleased to report that our business momentum continued into the second quarter |
| We reported record sales of $72.7 million in Q2 on solid growth across all our sales channels, which represents year-over-year growth of 33.1% |
| We continue to see strength in our D2C business, which represented over 50% of net sales for the second consecutive quarter |
| This momentum is driven by the launch of additional innovative products and expansion to our sales force that is producing more business wins, the growing international presence and increasing brand awareness of the Thorne name |
| On balance, our total portfolio continues to grow across our diversified customer base, which underscores the strength of our science-backed product offerings and trust in our high-quality brand |
| The strong top line performance was driven mainly by our direct-to-consumer or D2C business, which continues to perform well and exceed our internal expectations |
| Over the last several quarters, the strength of Thorne’s D2C portfolio has enabled us to increasingly shift into a more predictable sales model |
| We continue to acquire new customers efficiently with an LTV to CAC ratio of 4.0, and our net promoter score of 68 remains well above industry norms |
| Through this success, we have experienced strong growth in subscription volumes |
| Thorne.com subscriptions are up approximately 60% on a year-over-year basis from strength in both daily foundation products, as well as more unique and targeted products for sports performance and metabolic health |
| We also continue to see healthy retention rates, which is not surprising as the more often a customer uses our wellness products, the more likely they are to remain with us |
| We remain confident that based on our continued strength in our business, we can achieve this updated guidance |
| We expect continued momentum across our business as we enter the second half of the year |
| These dynamics underlie our strong top line performance as we generate a sustainable and more predictable income stream from our growing loyal customer base around the globe |
| In addition to strong sales growth, we also saw a nice improvement in our margins |
| Second quarter gross margin of 55.9% represents a more than 100 basis point improvement over Q2 of last year |
| D2C growth was primarily driven by favorable pricing increases, product rationalization and our ever-expanding customer base |
| We reported adjusted EBITDA of $12.5 million, a significant increase over the prior year period loss of $1.3 million, which was driven mainly by improved gross margin, efficient marketing spend and operating leverage |
| Our strong sales performance continues to be underpinned by healthy growth in unique new customers, which increased approximately 86% over Q2 of last year, with the number of active subscriptions up over 60% |
| I’m also pleased to note that we are starting to see growth in our Asia Pac business |
| By doubling in size to support sales upward of $750 million, we will be able to achieve economies from scale at far superior levels while expanding our production capabilities and lab space in support of our R&D operations and product development |
| On balance, our G&A costs on their own have continued to be extremely efficient and we gain leverage benefits from economies of scale where and when possible |
| We believe more personalized data-driven strategies with high-impact influencers will benefit our retention through higher engagement with new customers elevate the brand and drive customer acquisition at scale |
| Those increases helped to drive 39.3% sales growth in our B2C channel, which was also up 8.8% on a sequential quarter basis |
| We have seen nice sales growth in metabolism-related offerings and believe that metabolomics is fast becoming one of the most valuable measurements to assess the overall health status of an individual on a real-time basis |
| Statement |
|---|
| We also still expect that our margins and free cash flow will be compressed relative to historical norms during our plant expansion before gradually increasing once expansion is complete |
| Looking ahead, in H2, we expect some margin compression from incremental labor and overhead as we walk through capacity constraints that will require temporary use of command to help keep pace with demand, while we complete the expansion over the next few quarters |
| Adjusted diluted EPS for Q2 was $0.15 versus a loss of $0.05 per share in the second quarter of last year |
| However, as we ramp up capacity, the absorption in that works differently and our cost of production will come down significantly |
| The plant expansion creates a low watermark for our total liquidity this year before an anticipated steady recovery next year |
| Once our new world-class production facility is fully operational in Q1 2024, the capacity constraints we experienced from time to time are not expected to be an ongoing hurdle |
| We’ve already taken the hit and don’t see the Russian-Ukraine situation turning around positively |
| With no other significant capital projects in the pipeline, upon completing construction, we expect to reverse the negative free cash flow that we have been experiencing mid-project |
| Our marketing expense for the second quarter was $10 million, down 36.6% and representing 13.8% of Q2 net sales |
| Second quarter SG&A expense of $22.5 million was up 21.4% year-over-year and represented 30.9% of sales, a decrease of 300 basis points year-over-year |
| With competition from nearly 4,000 other product nominations globally, we couldn’t be more pleased to be recognized among such a large number of cutting-edge technologies and new innovations |
| With the trend of our generally higher end consumer, continuing to hold thus far, it’s clear that while there has been pullback in spending on discretionary items at the macro level, spending on products that people depend on for the health and wellness goals has stayed more insulated |
Please consider a small donation if you think this website provides you with relevant information